TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02760316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 10 mg
Description: Oral suspension Multiple doses 5 days of treatment Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 20 mg
Description: Oral suspension Multiple doses 5 days of treatment Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 40 mg
Description: Oral suspension Multiple doses 5 days of treatment Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 80 mg
Description: Oral suspension Multiple doses 5 days of treatment Once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 20 mg
Description: Oral Multiple doses 5 days of treatment Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 125 mg
Description: Oral Multiple doses 5 days of treatment Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 155 mg
Description: Oral Multiple doses 5 days of treatment Once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 5 mg
Description: Oral Multiple doses 5 days of treatment Once daily
Study: NCT04311983

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Quitline
Description: Tobacco quitlines provide phone counseling from a quit coach, often supplemented with NRT (nicotine replacement therapy), a quit guide, text messages, or other support. Smokers can call directly or consent to be called by the quitline (fax-back).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Quitline
Description: Tobacco quitlines provide phone counseling from a quit coach, often supplemented with NRT (nicotine replacement therapy), a quit guide, text messages, or other support. Smokers can call directly or consent to be called by the quitline (fax-back).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke Free Home
Description: The intervention guides participants though a 5-step process: (1) deciding to create a smoke-free home; (2) talking about it with household members; (3) setting a date for the home to become smoke-free; (4) making the home smoke-free; and (5) keeping the home smoke-free. Progress from one step to the next is facilitated over a 6-week period by three mailings sent to participants' homes and one telephone counseling call delivered by a trained smoke free homes coach.
Study: NCT04148885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Patients firstly receive nab-paclitaxel 100 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Patients secondly receive carboplatin AUC=5 (iv, 30 minutes) on days 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study: NCT02558543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stromal Vascular fraction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer lactate
Study: NCT01623011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Sub-acromial Decompression Surgery
Description: The procedure involves insertion of the arthroscope into the glenohumeral joint where the joint surface is inspected along with the intra-articular portion of the long head of biceps and the joint surface of the rotator cuff tendons. The arthroscope is then inserted into the sub-acromial bursa which lies outside the rotator cuff tendons and beneath the acromion process of the scapula. In the bursa the acromion and superior surface of the rotator cuff are assessed to ensure the coracoacromial ligament and the AC joint remains intact. The projecting under surface of the distal part of the acromion is resected.
Study: NCT02631889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcollation technology
Description: The use transcollation technology for dissection during lung surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional electrocautery
Description: The use of traditional Electrocautery for dissection during Lung Surgery
Study: NCT01623011

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Arthroscopy
Description: This is the surgical comparison group. The procedure is performed under general anaesthetic. Patients will undergo a routine investigational arthroscopy. The operation will be performed in exactly the same manner as Group ASAD. The exception is they will not undergo the decompression (bone spur removal). Tissues will be visualised and the joint will be washed out. The time spent in theatre will be similar to that for Group ASAD. These measures provide the AO group with the characteristics necessary to provide a reasonable comparison and account for the placebo effects of surgery.
Study: NCT03888066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer
Description: The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
Study: NCT01047514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Online Workshop
Description: 6 week, online, small group self-management workshop
Study: NCT03971474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Given IV
Study: NCT01623011

Intervention type: OTHER
Group type: OTHER
Intervention: Active Monitoring with Specialist Reassessment
Description: Patients will be advised that they will undergo active monitoring in the short term. They will attend a reassessment appointment 3 months after entering the study. Here, they will be asked to complete questionnaires related to their shoulder pain and undergo a clinical assessment for their shoulder. From an ethical standpoint it is emphasised that it is quite within normal practice to have a period of active monitoring.
Study: NCT02760316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 40 mg
Description: Oral Multiple doses 5 days of treatment Once daily
Study: NCT02776254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: START
Description: Point of care testing for rapid ART initiation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAG
Description: Community Adherence Group
Study: NCT04155372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Different Fluid Ingestion Rate
Description: The participants ingested sports drink in a volume equivalent to 150% of BW loss, in 30 min, 60 min, or 90min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Different Fluid Ingestion Rate
Description: The participants ingested sports drink in a volume equivalent to 150% of BW loss, in 30 min, 60 min, or 90min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Different Fluid Ingestion Rate
Description: The participants ingested sports drink in a volume equivalent to 150% of BW loss, in 30 min, 60 min, or 90min.
Study: NCT01851694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIP
Description: Each subject in this arm will receive GIP infusion and placebo during a GPA test.
Study: NCT04499898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic band ligation
Description: Endoscopic band ligation
Study: NCT04401943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online fatigue intervention
Description: on line teleconferencing fatigue intervention for 6 weeks on causes of fatigue, ways to protect joint and save energy, ways to manage stress, pain, good eating habits, and exercise.
Study: NCT03236779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry needling
Description: The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.
Study: NCT02565225

Intervention type: BEHAVIORAL
Intervention: RheumaLive App use

Intervention type: BEHAVIORAL
Intervention: RheumaLive App use
Study: NCT02981953

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardioband Tricuspid
Description: The Cardioband Adjustable implant is delivered and anchored to the tricuspid valve annulus by a transfemoral delivery system. The Cardioband TR will be deployed and adjusted under trans-esophageal and fluoroscopy guidance.
Study: NCT02776254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAG
Description: Community Adherence Group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UAG
Description: Urban Adherence Group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UAG
Description: Urban Adherence Group
Study: NCT04562883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The way of Cumulus-oocyte complexes (COC) culture
Description: Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The way of Cumulus-oocyte complexes (COC) culture
Description: Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.
Study: NCT04221321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 40 mg
Description: Atorvastatin 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40 mg
Description: Atorvastatin 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Description: Atorvastatin 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Description: Tegoprazan 50 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAPA114
Description: RAPA114 tablet
Study: NCT03662698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: GI is a relaxation technique involving the visualization of images and is considered an adjuvant cancer therapy.The GI intervention will include two hour-long meetings between the participant and a trained interventionist. The sessions will include direct, written, and audio delivery of one of three GI vignettes. The patient will be able to choose one of the three vignettes. The approximately twelve minute long vignettes included in the study will be: Taking a Walk, Healthy Cell Alliance for Treatment, and Daily Intention (32). Patients will also be given access to psychosocial support resources (i.e., clinical psychologists and social workers) at University of Colorado Cancer Center.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: This will include a tour of the treatment room and education about RT. Patients will also receive educational materials about RT including the process of RT and CT simulation, treatment side effects, pain management, and swallowing exercises. Participants in this condition will also have access to psychosocial support resources (i.e., clinical psychologists and social workers) at University of Colorado Cancer Center.
Study: NCT02776254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST-TRACK
Description: Prescription refill only
Study: NCT02842749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
Study: NCT03229941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Transfusion
Description: Blood Transfusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Transfusion
Description: Blood Transfusion
Study: NCT00446082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Study: NCT02356848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Intervention (TI)
Description: Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Current Practice (CP)
Description: this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease.
Study: NCT01277484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 1. Dose finding study (cycle 1-cycle4)~* Indicated dose for 5 consecutive days every 28 days~* Cohort 1: 5mg/m2 of decitabine~* Cohort 2 and 3:Dose escalation up to 15mg/m2 using a mechanism-based pharmacokinetic / pharmacodynamic model
Study: NCT02019875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: P450 inducer
Study: NCT02771782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine (SSI)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine (SSI)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDaP-IPV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDaP-IPV vaccine
Study: NCT04391660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% sodium hypochlorite solution
Description: Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress. This same antiseptic will be used at each dressing change.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% sodium hypochlorite solution and 70% ethanol
Description: Disinfection with a 0.5% sodium hypochlorite solution applied with a sterile compress preceded by an application of 70% ethanol with a sterile compress, for its immediate bactericidal action. 0.5% sodium hypochlorite solution will be applied once the alcohol has evaporated and the skin is visually dried. These same antiseptics will be used at each dressing change.
Study: NCT03424811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Health Intervention
Description: Mobile health intervention to promote healthy eating.
Study: NCT04586920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3509754
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3509754
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3509754
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3509754
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administered orally
Study: NCT03031327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricin 20µg/ml
Description: Lubricin 20µg/ml eye drops

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricin 50µg/ml
Description: Lubricin 50µg/ml eye drops

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate 0.18%
Description: Sodium hyaluronate (HA) 0.18% eye drops
Study: NCT03580707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BRV vs LEV in randomized double blinded, crossover fashion
Description: Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BRV vs LEV in randomized double blinded, crossover fashion
Description: Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
Study: NCT02019875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: P450 inducer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: P450 inducer
Study: NCT01768624

Intervention type: PROCEDURE
Intervention: dialysis, kidney transplant
Study: NCT03114475

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation
Description: CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
Study: NCT03971474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study: NCT04422600

Intervention type: OTHER
Intervention: There is no other intervention, only clinical treatment.
Description: The investigators will then correlate that exposure with neurodevelopmental outcomes.
Study: NCT01884142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Study: NCT01255449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol
Description: 400 mcg by inhalation
Study: NCT03290196

Intervention type: DRUG
Group type: OTHER
Intervention: EXPAREL 1.3 % in 20 ML Injection
Description: EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.
Study: NCT02160509

Intervention type: DEVICE
Intervention: IPhone based realtime remote ultrasound interpretation
Study: NCT04829773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palovarotene
Description: oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: oral syrup
Study: NCT02735161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strength training
Description: Two different muscle strength training protocols will be compared; one exercise session with high load/low repetitions (4 sets x 5RM) versus one exercise session with low load/high repetitions (2 sets x 25RM). Both session will be conducted at four different exercises; seated leg press, chest press, cable lat pull down and seated rowing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Description: Two different endurance exercise training protocols will be compared; one exercise sessions is interval training with high intensity (85-95% of HRmax) versus one of moderate intensity (70-75% of HRmax) with longer duration.
Study: NCT00954642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose
Study: NCT00247052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: diclofenac 50 mg bid versus placebo bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: diclofenac 100 mg per day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo